Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 12341
Country/Region: Vietnam
Year: 2018
Main Partner: Vietnam Nurses' Association
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: USDOD
Total Funding: $309,980 Additional Pipeline Funding: $525,098

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $38,794
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $55,864
Strategic Information (HVSI) $7,448
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $40,346
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $45,311
Sexual Prevention: Other Sexual Prevention (HVOP) $110,176
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $12,041
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST 25-29, Female, Negative 2019 1,548
HTS_TST 25-29, Female, Negative 2019 996
HTS_TST 25-29, Female, Negative 2019 6
HTS_TST 25-29, Female, Negative 2019 206
HTS_TST 25-29, Male, Negative 2019 4,644
HTS_TST 25-29, Male, Negative 2019 26
HTS_TST 25-29, Male, Negative 2019 620
HTS_TST 30-34, Female, Negative 2019 1,548
HTS_TST 30-34, Female, Negative 2019 664
HTS_TST 30-34, Female, Negative 2019 7
HTS_TST 30-34, Female, Negative 2019 206
HTS_TST 30-34, Male, Negative 2019 4,644
HTS_TST 30-34, Male, Negative 2019 27
HTS_TST 30-34, Male, Negative 2019 620
HTS_TST 35-39, Female, Negative 2019 2,167
HTS_TST 35-39, Female, Negative 2019 15
HTS_TST 35-39, Female, Negative 2019 289
HTS_TST 35-39, Male, Negative 2019 6,500
HTS_TST 35-39, Male, Negative 2019 60
HTS_TST 35-39, Male, Negative 2019 867
HTS_TST 40-49, Female, Negative 2019 929
HTS_TST 40-49, Female, Negative 2019 4
HTS_TST 40-49, Female, Negative 2019 124
HTS_TST 40-49, Male, Negative 2019 2,787
HTS_TST 40-49, Male, Negative 2019 19
HTS_TST 40-49, Male, Negative 2019 371
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 30,000
HTS_TST_POS 30-34, Female, Positive 2019 10
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 21
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 8
HTS_TST_POS 35-39, Female, Positive 2019 15
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Male, Positive 2019 30
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 35-39, Male, Positive 2019 9
PP_PREV Age/sex: 20-24 Male 2019 50,000
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 50,000
PP_PREV Sum of Age/Sex disaggregates 2019 50,000
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 34
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 138
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 172
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 172
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 34
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 138
TX_CURR 25-29, Female, Positive 2019 6
TX_CURR 25-29, Female, Positive 2019 4
TX_CURR 25-29, Male, Positive 2019 21
TX_CURR 25-29, Male, Positive 2019 14
TX_CURR 30-34, Female, Positive 2019 16
TX_CURR 30-34, Female, Positive 2019 16
TX_CURR 30-34, Male, Positive 2019 46
TX_CURR 30-34, Male, Positive 2019 31
TX_CURR 35-39, Female, Positive 2019 18
TX_CURR 35-39, Female, Positive 2019 22
TX_CURR 35-39, Male, Positive 2019 52
TX_CURR 35-39, Male, Positive 2019 48
TX_CURR 40-49, Female, Positive 2019 12
TX_CURR 40-49, Female, Positive 2019 10
TX_CURR 40-49, Male, Positive 2019 34
TX_CURR 40-49, Male, Positive 2019 7
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 205
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 152
TX_NEW 25-29, Female, Positive 2019 3
TX_NEW 25-29, Female, Positive 2019 5
TX_NEW 25-29, Male, Positive 2019 5
TX_NEW 25-29, Male, Positive 2019 8
TX_NEW 30-34, Female, Positive 2019 3
TX_NEW 30-34, Female, Positive 2019 4
TX_NEW 30-34, Male, Positive 2019 6
TX_NEW 30-34, Male, Positive 2019 9
TX_NEW 35-39, Female, Positive 2019 1
TX_NEW 35-39, Female, Positive 2019 1
TX_NEW 35-39, Male, Positive 2019 3
TX_NEW 35-39, Male, Positive 2019 5
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 21
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 32
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 205
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 152
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 52
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 52
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 153
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 100
TX_PVLS_den Denominator: Indication: Routine 2019 205
TX_PVLS_den Denominator: Indication: Routine 2019 152